Source comparison
CJC-1295 No DAC vs Modified Sermorelin vs GHRH (1-29)
CJC-1295 No DAC ~30 minutes 8–12 ng/mL at 100 mcg dose 2–3× daily Pulsatile, returns to baseline in 24h Preserves natural feedback; minimal desensitisation over 8–12 weeks Modified Sermorelin (GHRH 1-29) 10–20 minutes 6–10 ng/mL at 100 mcg dose 3× daily minimu
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- ~30 minutes
- 8–12 ng/mL at 100 mcg dose
- 2–3× daily
- Pulsatile, returns to baseline in 24h
- Preserves natural feedback; minimal desensitisation over 8–12 weeks
- Modified Sermorelin (GHRH 1-29)
- 10–20 minutes
- 6–10 ng/mL at 100 mcg dose
- 3× daily minimum
- Pulsatile, baseline return in 18–24h
- Shorter half-life requires more frequent dosing; identical receptor mechanism
- CJC-1295 with DAC
- 6–8 days
- Sustained 3–5 ng/mL elevation
- 1× weekly
- Sustained 1.5–2.0× baseline IGF-1
- Receptor desensitisation observed after 4–6 weeks; feedback suppression probable
- Native GHRH (1-44)
- 7–10 minutes
- 4–8 ng/mL (IV bolus only)
- Not practical for subcutaneous use
- Pulse only. No sustained elevation
- Rapidly degraded by DPP-4; requires continuous IV infusion for sustained effect
- Bottom Line: CJC-1295 No DAC offers the optimal balance between pulse amplitude and dosing practicality. Long enough to produce meaningful GH release but short enough to avoid suppressing endogenous secretion. Sermorelin requires more frequent administration but costs less per dose. The DAC-modified version simplifies dosing to once weekly but sacrifices physiological pulsatility and demonstrates diminishing returns beyond the first month.